NeuroSense Therapeutics (NRSN) Common Equity (2020 - 2025)
NeuroSense Therapeutics (NRSN) posted Common Equity of -$1.6 million for Q4 2025, down 200.58% sequentially from -$519000.0 in Q2 2025, and down 160.39% YoY from $2.6 million in Q4 2024.
NeuroSense Therapeutics (NRSN) Common Equity (2020 - 2025) Analysis & Trends
NeuroSense Therapeutics has reported Common Equity for 6 years, with the latest figure at -$1.6 million in Q4 2025.
- Quarterly Common Equity fell 160.39% year-over-year to -$1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.6 million (down 160.39% YoY) and the FY2025 annual result came in at -$1.6 million, down 160.39% from the prior year.
- Common Equity slipped to -$1.6 million in Q4 2025 per NRSN's latest filing, from -$519000.0 in the prior quarter.
- Over five years, Common Equity peaked at $12.1 million in Q1 2022 and troughed at -$7.0 million in Q1 2024.
- A 5-year average of $2.3 million and a median of $1.1 million in 2021 frame the typical range for Common Equity.
- The sharpest annual moves came in 2021 and 2024: Common Equity surged 1266.62% in 2021, then sank 1337.76% in 2024.
- Over 5 years, Common Equity stood at $9.0 million in 2021, then slumped by 35.11% to $5.8 million in 2022, then slumped by 130.1% to -$1.8 million in 2023, then soared by 246.84% to $2.6 million in 2024, then slumped by 160.39% to -$1.6 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered -$1.6 million, -$519000.0, and $2.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - | -1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.56 Mn |
| Jun 30, 2025 | -519,000.00 |
| Dec 31, 2024 | 2.58 Mn |
| Sep 30, 2024 | -2.82 Mn |
| Jun 30, 2024 | -1.70 Mn |
| Mar 31, 2024 | -6.99 Mn |
| Dec 31, 2023 | -1.76 Mn |
| Sep 30, 2023 | -196,000.00 |
| Jun 30, 2023 | 1.27 Mn |
| Mar 31, 2023 | 2.89 Mn |
| Dec 31, 2022 | 5.84 Mn |
| Sep 30, 2022 | 7.85 Mn |
| Jun 30, 2022 | 9.84 Mn |
| Mar 31, 2022 | 12.11 Mn |
| Dec 31, 2021 | 9.01 Mn |
| Jun 30, 2021 | 937,000.00 |
| Dec 31, 2020 | 659,000.00 |